# **NCI Director's Report**

W. Kimryn Rathmell, M.D., Ph.D. Director, National Cancer Institute

17th Virtual Meeting of the Frederick National Laboratory Advisory Committee October 23, 2024

@NCIDirector @TheNCI



# Today's Topics

- 1. Recent News/Updates
- 2. Budget Updates
  - NEW: NCI FY26 Annual Plan and Professional Judgment Budget Proposal
- 3. Research and Program Highlights
- 4. Q&A / Discussion



# **Recent News and Updates**



# Recent visits and meetings with collaborators (U.S. and international)

\*not comprehensive



NCORP sites: Kansas (top), New York (bottom)





U Chicago research symposium



MD-PhD national conference (Colorado)



WHO Collaborating Center for Global Cancer Control



U.S. Ambassador to Australia



National Cancer Center, Japan



#### **Iowa Cancer Summit**









## **Recent White House engagements**

White House Office of
Management and Budget
examiners visited NIH to
learn about Cancer
Moonshot projects

THE PRESIDENT AND FIRST LADY'S

**CANCER MOONSHOT** 

**ENDING CANCER AS WE KNOW IT** 

visited for an overview of NCI at Frederick and efforts aimed at eliminating HPV-driven tumors



Office of Management and
Budget visited NCI at
Frederick to see the science
(and needs to advance
progress) up close



#### **NCI Frederick**





## **NCI Senior Leadership Appointment**



Kristin Komschlies, Ph.D.

Associate Director for NCI Frederick

## **NCI Senior Leadership Appointment**



Sanya A. Springfield, Ph.D.

Acting Deputy Director, Cancer Health Equity and Inclusion Director, Center for Cancer Health Equity

## **NCI Senior Leadership Updates**



Peter Garrett
Director, Center for External
Affairs (CEA)\*



Amber Lowery

Deputy Director for Management /

Executive Officer

# Leadership retreat – key takeaways (July 16, 2024)

#### Goal:

To identify 1-3 areas of focus for which NCI can demonstrate output and value to the public.



TRUST EARLY ONSET CANCERS

**DATA SCIENCE** 

**TRAINING** 

COMMUNICATION

**CANCER BIOLOGY** 

**ARTIFICIAL INTELLIGENCE** 

**PREVENTION** 

**IMMUNOLOGY** 

**OBESITY** 

**VACCINES** 




# **Budget Updates**

NCI FY26 Annual Plan and Professional Judgment Budget Proposal



# NCI Fiscal Year 2026 Annual Plan and Professional Judgment Budget Proposal



https://www.cancer.gov/research/leading-progress



## FY26 Professional Judgment Budget Proposal

FY24 NCI Appropriation	\$7,224	
FY25 President's Budget Proposal*	\$9,287	
Proposed Increase over FY25 President's Budget Proposal (Allocation by category)	\$2,179	\$479 Cancer Biology Research \$338 Cancer Prevention Research \$457 Cancer Detection & Diagnosis Research \$534 Cancer Treatment Research \$175 Public Health & Cancer Control Research \$196 Training & Infrastructure
FY26 TOTAL	\$11,466**	

(Dollars in millions)

#### FY26 Annual Plan and Professional Judgment Budget Proposal Highlighted Scientific Opportunities



TACKLING THE EMERGENCE OF EARLY-ONSET CANCERS IN YOUNG ADULTS



APPROACHING CANCER AS A DISEASE THAT AFFECTS THE ENTIRE BODY



ALLEVIATING FINANCIAL TOXICITY FOR CANCER SURVIVORS AND CAREGIVERS



**EXPANDING THE UTILITY OF CANCER-TARGETING VACCINES** 

#### FY26 Annual Plan and Professional Judgment Budget Proposal

Stories of Cancer Research




Opting for a Novel
Combination
Treatment for
Resistant Aggressive
B-Cell Lymphoma

Enrolling in NCI's trial of a 5drug combination called ViPOR for non-Hodgkin lymphoma changed Justin's life.



Treating Precancer in
Low-Resource
Settings to Prevent
Cervical Cancer

Read about the work of Leeya Pinder, M.D., M.P.H., an NCI grant recipient and Cancer Moonshot Scholar.



<u>Lighting the Way to</u>
<u>Detect Tumors During</u>
<u>Surgery</u>

CYTALUX, a molecule that makes tumors glow in the operating room, was developed with support from NCI



# **NCI's Budget Proposals and Appropriations**

What it would cost to do what is expected

What we are working with

-			
	NCI's Professional Judgment Budget Proposal	Actual NCI Budget	
FY 2023	\$7.766B	\$7.3B	
FY 2024	\$9.988B	\$7.22B (\$120M increase to the base but an overall \$96M decrease)	
FY 2025	\$11.466B	? Current CR FY25 expires Preside	
FY 2026	\$11.466B	? 12/20 Budg	

'S

\$9.287B


# Research and Program Highlights



## **Research Highlights**



Zebrafish may be a relevant model for studying transport of drugs across the blood-brain barrier



Newly identified antibodies block many influenza strains in laboratory tests



Mpox vaccine provides strong protection in adolescents



# What I need from you today...

How can FNL best function as a resource of the extramural community?

Are there areas of future impact that we should consider offering through the FNL contract mechanism?

- Your inputs on individual programs are immensely valuable
- Your suggestions regarding programmatic factors help us level set and ensure we are staying out in front

Always – we welcome suggestions for ways to move forward, faster...

# Thank You!

www.cancer.gov/espanol
1-800-4-CANCER
NClinfo@nih.gov
@NCIDirector



@TheNCI